A randomized trial in Liverpool found that endotracheal surfactant treatment did not reduce intubation duration in infants with severe bronchiolitis.
The study showed no benefit from surfactant in lowering intubation time
Researchers administered surfactant via endotracheal tube to infants hospitalized with severe bronchiolitis and compared outcomes to a control group receiving standard care. The primary endpoint — duration of invasive ventilation — showed no statistically significant difference between groups. The findings were published in Lancet Respiratory Medicine in April 2026.
Surfactant remains standard for preterm lung immaturity but not viral bronchiolitis
Surfactant therapy is well-established for neonatal respiratory distress syndrome caused by surfactant deficiency in premature infants. However, bronchiolitis — typically driven by respiratory syncytial virus — involves inflammation and mucus plugging rather than primary surfactant dysfunction. The study reinforces that pathophysiological differences limit surfactant’s utility outside neonatal indications.
What is bronchiolitis and who is most at risk?
Bronchiolitis is an acute lower respiratory infection primarily affecting children under two years ancient, peaking in infancy. It is most commonly caused by RSV and leads to airway obstruction, wheezing, and respiratory distress requiring hospitalization in severe cases.
Why was surfactant tested in this population despite differing mechanisms?
Prior observational data and theoretical models suggested surfactant inactivation or dysfunction might contribute to lung injury in severe viral bronchiolitis, prompting investigation into exogenous surfactant as a potential therapeutic adjunct despite lack of evidence for deficiency-driven pathology.
